Monalizumab is named as a drug or biological intervention in 4 clinical trials in our USA, UK, Ireland and China trial registers, 1 of which is recruiting. Lead sponsors include AstraZeneca (3) and MedImmune LLC (1). Registered phases: Phase 3, Phase 2 and Phase 1/2. Conditions studied include Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Non-Small Cell Lung Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer |
Phase 2 | Recruiting |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer Squamous Cell Carcinoma of the Head and Neck |
Phase 3 | Active, closed |
| NCT05221840 | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer |
Phase 3 | Active, closed |
| NCT02671435 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-small Cell Lung Cancer | 1 |
| Squamous Cell Carcinoma of the Head and Neck | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Advanced Solid Tumors | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 3 |
| MedImmune LLC | 1 |
| Register | Monalizumab trials |
|---|---|
| Clinical trials in USA | 4 |
| Clinical trials in UK | 3 |
| Clinical trials in Ireland | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Monalizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Monalizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.